As the COVID-19 outbreak increases pressure on the UK’s NHS services and frontline staff, leading scientists and businesses are taking on new initiatives to tackle the outbreak. As there is currently no treatment or vaccine for this virus, researchers are working at unprecedented speed to accelerate the development of a treatment. Businesses are putting in more effort to help those on the frontline of this global crisis.
INEOS has managed to built a hand sanitzer plant in the UK and will soon open the facility in Germany, aiming to produce 1m bottles per month each to address a supply shortage across the UK and Europe.
BASF will soon be producing hand sanitizers at its petrochemicals hub in Germany to address the shortage in the region.
Ramping up the supply of PPE, AstraZeneca is donating nine million face masks to support healthcare workers around the world. Alongside this, AstraZeneca is accelerating the development of its diagnostic testing capabilities to scale-up screening and is also partnering with governments on existing screening programmes.
Pharmaceutical company Novartis UK, along with several others, is making available a set of compounds from its library that it considers are suitable for in vitro antiviral testing.
GSK has announced that is donating $10 million to the COVID-19 Solidarity Response Fund. The Fund was created by the World Health Organisation (WHO) to help WHO and its partners to prevent, detect and manage the pandemic
Alongside the efforts and initiatives from industries, to continue to aid those on the frontline of this global crisis, social distancing interventions must remain to flatten the curve.
Research and data modelling has shown that policy strategies, such as social distancing and isolation interventions which aim to suppress the rate of transmission, might reduce death and peak healthcare demand by two-thirds.
Stopping non-essential contact can flatten the curve. Suppressing the curve means we may still experience the same number of people becoming infected but over a longer period of time and at a slower rate, reducing the stress on our healthcare system.
2019 has been declared by UNESCO as the Year of the Periodic Table. To celebrate, we are releasing a series of blogs about our favourite elements and their importance to the chemical industry. Today’s blog focuses on Nickel.
Nickel, a silvery-white lustrous metal with a slight golden tinge may be commonly known as a US five cent coin, however, today nickel is one of the most widely used metals. According to the Nickel Institute, the metal is used in over 300,000 various products. It is also commonly used as a catalyst for hydrogeneration, cathodes for batteries and metal surface treatments.
Nickel in batteries:
Historically, nickel has been widely used in batteries; nickel cadmium (NiCd) and in nickel metal hydride (NiMH) rechargeable batteries. These batteries were used in power tools and early digital cameras. Their success as batteries in portable devices became a stepping stone that led to the significant use of NiMH batteries in car vehicles, such as the Toyota Prius.
The demand for nickel will increase even further as we move away from fossil fuel energy. More energy wll need to be stored in the cathode part of lithium-ion batteries as a result.
Socio-economic data on nickel demonstrates the importance the nickel value chain has on industries, which includes mining through end use to recycling.
The data reflects that globally, the nickel value chain supports a large number of jobs, primarily ones in manufacturing and chemical engineering. The output generated by nickel related industries is approximately €130bn, providing around 750,000 jobs.
Nickel is fully recyclable without its qualities being downgraded, making it very sustainable. It is difficult to destroy and its qualities – corrosion resistance, high-temperature stability, strength, recyclability, and catalytic and electromagnetic properties are enabling qualities required for sustainability.